Multivitamins: All participants will receive multivitamins (vitatron) capsule once daily, for 12 weeks.
Connective tissue massage: Connective tissue massage will be applied on (Sacral, lumbar, last thoracic vertebrae-T12, and subcostal regions), 2 sessions/week for 20 minutes each session for 12 weeks. Treatment will begin 3 days before menstruation to the 4th day of menstruation for 3 successive menstrual cycles.
Study summary
This study will be conducted to investigate the effect of connective tissue massage on premenstrual syndrome.
Eligibility
Sex
FEMALE
Min age
17 Years
Max age
25 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Virgin adolescent females diagnosed with premenstrual syndrome.
* Their age will be ranged from 17-25 years (3 years post puberty).
* Their body mass index (BMI) will be less than 30 kg/m2 .
* All are of regular menstrual cycles.
* All of them suffering from moderate and severe PMS.
Exclusion Criteria:
Participants will be excluded from this study if they have
* Any pathological finding in the pelvic cavity as polycystic ovarian syndrome, endometriosis, and pelvic inflammatory diseases.
* Irregular menstruation.
* Any history of gynecological intervention.
* Open wounds, weak/broken bones or fractures.
Primary outcome measure(s)
Pain intensity — 3 months Degrees of menstrual pain will be assessed using a VAS for all participants before and after treatment, which is a method of representing pain on a 10 cm linear scale.
A score of zero means "No pain" and 10 means "a very high degree of pain".
Premenstrual syndrome severity — 3 months Severity of premenstrual symptoms will be assessed by using the Menstrual Distress Questionnaire (MDQ). Each participant will examine symptom categories (pain, concentration, water retention, behavior changes, negative effect, autonomic reaction, arousal and control) Participants are asked to report the symptoms experienced during their most recent menstrual period, using a rating scale. Responses ranged from (0) No experience of the symptom, (1) mild, (2) moderate, (3) severe and (4) very severe disabling symptoms. Overall scores are interpreted as follows: \>50- mild, 50 to 70- moderate and \>70 severe
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
